The novel HDAC6 inhibitor 9r induces anti-tumor responses by enhancing T cell response and inducing MHC class II signaling pathways in esophageal cancer.

OBJECTIVE

This study aimed to investigate the therapeutic potential of the novel HDAC6 inhibitor 9r in esophageal cancer (EC). Specifically, it focused on evaluating 9r's ability to inhibit tumor growth, migration, and apoptosis while enhancing antitumor immunity through the modulation of MHC class II signaling pathways.

METHODS

The study employed in vitro experiments using TE-1 and MEC25 esophageal cancer cells to assess anti-tumor effects of compound 9r. RNA sequencing and bioinformatics analysis were utilized to explore the molecular mechanisms underlying its action, particularly its impact on MHC class II pathways. In vivo experiments were conducted using a murine MEC25 cell xenograft model to evaluate tumor growth inhibition and immune activation. Techniques such as flow cytometry, RT-qPCR, Western blotting, and immunohistochemistry were used for functional validation.

RESULTS

Compound 9r significantly suppressed TE-1 cell proliferation, migration, and induced apoptosis in vitro. RNA-seq analysis revealed that 9r upregulated MHC class II-related genes (e.g., HLA-DRA, CD74), which were further enhanced by IFN-γ co-stimulation. In vivo studies demonstrated that 9r inhibited tumor growth in MEC25 xenografts while increasing CD4+ and CD8+ T cell infiltration in both tumor tissue and spleen. Immunohistochemistry confirmed reduced Ki-67 expression and increased acetylation of α-tubulin, indicating HDAC6 inhibition. The compound exhibited minimal toxicity in treated mice.

CONCLUSION

The HDAC6 inhibitor 9r effectively suppresses esophageal cancer progression through dual mechanisms: direct tumor inhibition and enhancement of antitumor immune responses via MHC class II pathway activation. These findings establish 9r as a promising candidate for esophageal cancer treatment and provide a foundation for further clinical development.